Valuewalk.com
0
All posts from Valuewalk.com
Valuewalk.com in Valuewalk.com,

Kyle Bass Petition To Challenge Biogen Patent Denied

The Patent Trial and Appeal Board of the United States Patent and Trademark Office (USPTO) declined to hold a trial in connection with the petition of hedge fund manager Kyle Bass to challenge the validity of Biogen’s patent on Tecfidera, a treatment for multiple sclerosis.

Biogen Kyle Bass

Kyle Bass through the Coalition for Affordable Drugs is challenging some of the patents of pharmaceutical companies including Biogen, Celgene and Pharmacyclics. According to the hedge fund manager, his intention is to “lower drug prices for Medicare and everyone.

The Coalition for Affordable Drugs started filing petitions to eliminate major drug patents through a process called an inter-partes review. Kyle Bass’ coalition filed 16 patent petitions with the Patent Trial and Appeal Board.

Kyle Bass argument on Biogen’s Tecfidera patent

Kyle Bass...


More